Back to Search Start Over

Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies

Authors :
Carlos A. Ramos
Rima M. Saliba
Leandro de Pádua
Ola Khorshid
Elizabeth J. Shpall
Sergio Giralt
Poliana A. Patah
Chitra M. Hosing
Uday R. Popat
Gabriela Rondon
Issa F. Khouri
Yago L. Nieto
Richard E. Champlin
Marcos de Lima
Source :
Haematologica, Vol 94, Iss 2 (2009)
Publication Year :
2009
Publisher :
Ferrata Storti Foundation, 2009.

Abstract

Background Because hepatitis C virus infection causes hepatic and immunological dysfunction, we hypothesized that seropositivity for this virus could be associated with increased non-relapse mortality after allogeneic hematopoietic stem cell transplantation.Design and Methods We performed a case-control study of the outcomes of patients who were hepatitis C virus seropositive at the time of allogeneic hematopoietic stem cell transplantation (N=31). Patients positive for hepatitis C virus were considered candidates for stem cell transplantation only if they had no significant evidence of hepatic dysfunction. Matched controls (N=31) were seronegative for viral hepatitides and were paired according to age, diagnosis, disease stage, conditioning regimen and donor type. We also compared the hepatitis C virus seropositive patients to all seronegative patients (all controls, N=1800) transplanted during the same period, to adjust for other confounding effects.Results The median age of the seropositive patients was 49 (range 26–72); 15 had acute myeloid leukemia/myelodysplastic syndrome, 6 had chronic myeloid leukemia/myeloproliferative disease, 6 non-Hodgkin’s lymphoma, 2 myeloma, 1 acute lymphocytic leukemia and 1 Hodgkin’s lymphoma; 61% had poor risk disease; 68% had related donors; 68% received reduced intensity conditioning; 7 patients had mildly abnormal alanine transaminase levels (all less than three times the upper limit of normal) and 1 patient had minimally elevated bilirubin. These characteristics were similar to those of the matched control group. Median overall survival was 3, 18 and 20 months, and 1-year survival was 29%, 56% and 56%, in the hepatitis C virus, matched and all controls groups, respectively (hazard ratio for death 3.1, 95% confidence interval 1.9–5.6, p

Details

Language :
English
ISSN :
03906078 and 15928721
Volume :
94
Issue :
2
Database :
Directory of Open Access Journals
Journal :
Haematologica
Publication Type :
Academic Journal
Accession number :
edsdoj.3151bb5429c940bb879f445cc0649306
Document Type :
article
Full Text :
https://doi.org/10.3324/haematol.13756